Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

Digest.

McClain Z, Pawlowski J, Tindall DW.

Adapt Phys Activ Q. 2019 Apr 1;36(2):304-305. doi: 10.1123/apaq.2019-0026. Epub 2019 Mar 21. No abstract available.

PMID:
30896978
2.

Androgen Mediation-and Antiandrogens Mitigation-of the Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series.

Le-Rademacher JG, Rowland K, Atherton PJ, Dakhil C, Sun Z, Tan A, Schmidt L, Nguyen PL, Radecki Breitkopf C, Pittelkow M, Tindall D, Menon S, Jatoi A.

Am J Hosp Palliat Care. 2019 Jun;36(6):519-525. doi: 10.1177/1049909118819820. Epub 2019 Jan 2.

PMID:
30602311
3.

Digest.

McClain Z, Pitchford EA, Tindall DW.

Adapt Phys Activ Q. 2018 Dec 20:1-2. doi: 10.1123/apaq.2018-0185. [Epub ahead of print] No abstract available.

PMID:
30572712
4.

Digest October 2018

McClain Z, Tindall DW, Pitchford EA.

Adapt Phys Activ Q. 2018 Oct 26:1-2. doi: 10.1123/apaq.2018-0124. [Epub ahead of print] No abstract available.

PMID:
30366500
5.

Digest.

Pawlowski J, Pitchford EA, Tindall DW, Lee SH.

Adapt Phys Activ Q. 2018 Apr 1;35(2):245-248. doi: 10.1123/apaq.2018-0021. No abstract available.

PMID:
29580064
6.

Structure and Reactivity of Half-Sandwich Rh(+3) and Ir(+3) Carbene Complexes. Catalytic Metathesis of Azobenzene Derivatives.

Tindall DJ, Werlé C, Goddard R, Philipps P, Farès C, Fürstner A.

J Am Chem Soc. 2018 Feb 7;140(5):1884-1893. doi: 10.1021/jacs.7b12673. Epub 2018 Jan 29.

PMID:
29332395
7.

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.

He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H.

Nucleic Acids Res. 2018 Feb 28;46(4):1895-1911. doi: 10.1093/nar/gkx1306.

8.

Digest.

McClain Z, Pitchford EA, Webster EK, Tindall DW.

Adapt Phys Activ Q. 2017 Jul;34(3):340-342. doi: 10.1123/apaq.2017-0075. No abstract available.

PMID:
28727512
9.

Digest.

McClain Z, Tindall DW, Ku B, MacDonald M, Davidson J, MacDonald M, Lee SH, Webster EK.

Adapt Phys Activ Q. 2017 Apr;34(2):203-205. doi: 10.1123/apaq.2017-0067. No abstract available.

PMID:
28556767
10.

Digest.

McClain Z, Schenkelberg MA, Tindall DW.

Adapt Phys Activ Q. 2015 Oct;32(4):373-375. No abstract available.

PMID:
27740848
11.

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N.

Lancet Oncol. 2016 Oct;17(10):1435-1444. doi: 10.1016/S1470-2045(16)30227-3. Epub 2016 Aug 27.

12.

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.

Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H.

Cell Rep. 2016 Apr 19;15(3):599-610. doi: 10.1016/j.celrep.2016.03.038. Epub 2016 Apr 7.

13.

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL.

Cancer Res. 2015 Nov 15;75(22):4688-96. doi: 10.1158/0008-5472.CAN-15-0892. Epub 2015 Oct 2.

14.

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.

Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV.

Onco Targets Ther. 2015 Jul 30;8:1915-22. doi: 10.2147/OTT.S86637. eCollection 2015.

15.

Video Modeling to Teach Social-Game Behaviors.

Schenkelberg MA, McClain Z, Tyler K, Tindall DW.

Adapt Phys Activ Q. 2015 Jul;32(3):279-282. No abstract available.

PMID:
27715175
16.

Are androgen receptor variants a substitute for the full-length receptor?

Lu J, Van der Steen T, Tindall DJ.

Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10. Review.

PMID:
25666893
17.

A distinctive Canadian sociology?

Tindall DB.

Can Rev Sociol. 2014 Nov;51(4):395-401. No abstract available.

PMID:
25612390
18.

Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.

Zhang Q, Padi SK, Tindall DJ, Guo B.

Cell Death Dis. 2014 Oct 23;5:e1486. doi: 10.1038/cddis.2014.454.

19.

Introduction to manuscript by Prof. Donald S. Coffey.

Tindall DJ.

Asian J Urol. 2014 Oct;1(1):2. doi: 10.1016/j.ajur.2015.04.002. Epub 2015 Apr 16. No abstract available.

20.

The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.

Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, Van der Steen T, Boorjian SA, Kosari F, Vasmatzis G, Klee GG, Balk SP, Huang H, Wang C, Tindall DJ.

J Urol. 2015 Feb;193(2):690-8. doi: 10.1016/j.juro.2014.08.043. Epub 2014 Aug 14.

21.

Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.

Zhao Y, Tindall DJ, Huang H.

Int J Biol Sci. 2014 Jun 5;10(6):614-9. doi: 10.7150/ijbs.8389. eCollection 2014. Review.

22.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

Andriole GL, Bostwick DG, Gomella LG, Marberger M, Montorsi F, Tammela TL, Tindall DJ, Fowler IL, Garges HP, Wilson TH, Castro R.

Urology. 2014 Aug;84(2):393-9. doi: 10.1016/j.urology.2014.04.016. Epub 2014 Jun 7.

PMID:
24916669
23.

Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth.

Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV.

Mol Cancer Ther. 2014 May;13(5):1067-77. doi: 10.1158/1535-7163.MCT-13-0699. Epub 2014 Mar 27.

24.

Analyzing site selectivity in Rh2(esp)2-catalyzed intermolecular C-H amination reactions.

Bess EN, DeLuca RJ, Tindall DJ, Oderinde MS, Roizen JL, Du Bois J, Sigman MS.

J Am Chem Soc. 2014 Apr 16;136(15):5783-9. doi: 10.1021/ja5015508. Epub 2014 Apr 8.

25.

CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.

Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, Wang L, Yu C, Rizzardi A, Cheng L, Zhang J, Schmechel SC, Cheville JC, Van Deursen J, Tindall DJ, Huang H.

Cancer Res. 2014 Apr 1;74(7):2050-61. doi: 10.1158/0008-5472.CAN-13-1659. Epub 2014 Feb 3.

26.

p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.

Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H.

Cancer Res. 2014 Mar 15;74(6):1870-1880. doi: 10.1158/0008-5472.CAN-13-2485. Epub 2014 Jan 30.

27.

Imidazolidin-2-one: pseudosymmetry and twinning.

Taouss C, Jones PG, Tindall DJ.

Acta Crystallogr C. 2013 Dec 15;69(Pt 12):1534-6. doi: 10.1107/S0108270113030746. Epub 2013 Nov 15.

PMID:
24311506
28.

Posttranslational modification of the androgen receptor in prostate cancer.

van der Steen T, Tindall DJ, Huang H.

Int J Mol Sci. 2013 Jul 16;14(7):14833-59. doi: 10.3390/ijms140714833. Review.

29.

Androgen receptor: past, present and future.

Schmidt LJ, Tindall DJ.

Curr Drug Targets. 2013 Apr;14(4):401-7.

PMID:
23565753
30.

Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms.

Wang D, Lu J, Tindall DJ.

Cancer Lett. 2013 Jul 10;335(1):136-44. doi: 10.1016/j.canlet.2013.02.001. Epub 2013 Feb 9.

31.

TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells.

Eide T, Ramberg H, Glackin C, Tindall D, Taskén KA.

Cancer Cell Int. 2013 Jan 31;13(1):4. doi: 10.1186/1475-2867-13-4.

32.

Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance.

Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Hönscheid P, Sinicrope FA, Tindall DJ, Muders MH, Datta K.

Cancer Res. 2013 Jan 1;73(1):160-71. doi: 10.1158/0008-5472.CAN-11-3635. Epub 2012 Nov 13.

33.

Parting messages from current and former editors of the Journal of Andrology.

Bartke A, Orgebin-Crist MC, Desjardins C, Lewis R, Tindall D, Hamilton DW, Pryor JL, Schlegel PN, Hardy MP, Burnett AL, Darney SP, Sandlow J.

J Androl. 2012 Nov-Dec;33(6):1068-74. doi: 10.2164/jandrol.112.017475. Epub 2012 Aug 9.

PMID:
22879531
34.

Global methylation profiling for risk prediction of prostate cancer.

Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, Donkena KV.

Clin Cancer Res. 2012 May 15;18(10):2882-95. doi: 10.1158/1078-0432.CCR-11-2090.

35.

Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells.

Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV.

Evid Based Complement Alternat Med. 2012;2012:303019. doi: 10.1155/2012/303019. Epub 2012 Feb 22.

36.

RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.

Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV.

Mol Endocrinol. 2012 May;26(5):716-35. doi: 10.1210/me.2011-1130. Epub 2012 Mar 28.

37.

Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.

Campbell TJ, Tindall DJ, Figg WD.

Cancer Biol Ther. 2012 Mar;13(5):237-8. doi: 10.4161/cbt.19608. Epub 2012 Mar 1.

38.

Androgen receptor signaling in prostate cancer development and progression.

Lonergan PE, Tindall DJ.

J Carcinog. 2011;10:20. doi: 10.4103/1477-3163.83937. Epub 2011 Aug 23.

39.

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.

Ryan CJ, Tindall DJ.

J Clin Oncol. 2011 Sep 20;29(27):3651-8. doi: 10.1200/JCO.2011.35.2005. Epub 2011 Aug 22. Review.

PMID:
21859989
40.

Androgen action during prostate carcinogenesis.

Wang D, Tindall DJ.

Methods Mol Biol. 2011;776:25-44. doi: 10.1007/978-1-61779-243-4_2. Review.

PMID:
21796518
41.

Alternatively spliced androgen receptor variants.

Dehm SM, Tindall DJ.

Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96. doi: 10.1530/ERC-11-0141. Print 2011 Oct. Review.

42.

Androgen action in prostate cancer.

Basu S, Tindall DJ.

Horm Cancer. 2010 Oct;1(5):223-8. doi: 10.1007/s12672-010-0044-4. Review.

PMID:
21761368
43.

Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells.

Jiang J, Pan Y, Regan KM, Wu C, Zhang X, Tindall DJ, Huang H.

Prostate. 2012 Feb 1;72(2):225-32. doi: 10.1002/pros.21430. Epub 2011 May 31.

44.

Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer.

Dimonte G, Bergstralh EJ, Bolander ME, Karnes RJ, Tindall DJ.

Prostate. 2012 Feb;72(3):280-90. doi: 10.1002/pros.21429. Epub 2011 May 31.

45.

Targeting 5α-reductase for prostate cancer prevention and treatment.

Nacusi LP, Tindall DJ.

Nat Rev Urol. 2011 May 31;8(7):378-84. doi: 10.1038/nrurol.2011.67. Review.

46.

Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.

Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV.

AAPS J. 2011 Sep;13(3):365-77. doi: 10.1208/s12248-011-9279-4. Epub 2011 May 11.

47.

Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.

Lamont KR, Tindall DJ.

Mol Endocrinol. 2011 Jun;25(6):897-907. doi: 10.1210/me.2010-0469. Epub 2011 Mar 24. Review.

48.

Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.

Heemers HV, Schmidt LJ, Sun Z, Regan KM, Anderson SK, Duncan K, Wang D, Liu S, Ballman KV, Tindall DJ.

Cancer Res. 2011 Mar 1;71(5):1978-88. doi: 10.1158/0008-5472.CAN-10-2512. Epub 2011 Feb 15.

49.

Regulation of FOXO protein stability via ubiquitination and proteasome degradation.

Huang H, Tindall DJ.

Biochim Biophys Acta. 2011 Nov;1813(11):1961-4. doi: 10.1016/j.bbamcr.2011.01.007. Epub 2011 Jan 14. Review.

50.

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group.

J Urol. 2011 Jan;185(1):126-31. doi: 10.1016/j.juro.2010.09.011. Epub 2010 Nov 12.

PMID:
21074214

Supplemental Content

Loading ...
Support Center